The therapeutic potential of milk thistle in diabetes

Review of Diabetic Studies

Volumn 11, Issue 2, 2014, Pages 167-174

  Kazazis, Christos E ^a   Evangelopoulos, Angelos A ^b   Kollas, Aris ^c   Vallianou, Natalia G ^c  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b Roche Hellas Pharmaceutical Company   (Greece)

^c EVANGELISMOS HOSPITAL   (Greece)

Author keywords

Anti diabetic; Bioavailability; HbA1c; Milk thistle; PPAR gamma; Silibin; Type 2 diabetes

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CATALASE; CYTOCHROME P450 2E1; DIPEPTIDYL CARBOXYPEPTIDASE; GAMMA GLUTAMYLTRANSFERASE; GLUTATHIONE PEROXIDASE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; N (G), N (G) DIMETHYLARGININE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PYRUVATE KINASE; SILIBININ; STEROL REGULATORY ELEMENT BINDING PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; SUPEROXIDE DISMUTASE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; ANTIOBESITY AGENT; FLAVONOLIGNAN; PLANT EXTRACT; SILYMARIN;

ALCOHOL LIVER CIRRHOSIS; ANTIDIABETIC ACTIVITY; BERBERIS ARISTATA; BINDING AFFINITY; CREATININE BLOOD LEVEL; CYTOTOXICITY; DIABETES MELLITUS; DIABETIC NEUROPATHY; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG SAFETY; ELIMINATION HALF-LIFE; GALLBLADDER DISEASE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HEPATITIS C; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; INSULIN TOLERANCE TEST; INTESTINE ABSORPTION; KIDNEY FUNCTION; LIVER DISEASE; LIVER TOXICITY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXYGEN CONSUMPTION; PRIMARY SCLEROSING CHOLANGITIS; PRURITUS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SILYBUM MARIANUM; URINE VOLUME; ADVERSE EFFECTS; AGONISTS; ANIMAL; CHEMISTRY; DIABETES MELLITUS, TYPE 2; PHYTOTHERAPY; PLANT SEED; RAT;

ANIMALS; ANTI-OBESITY AGENTS; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; FLAVONOLIGNANS; HUMANS; HYPOGLYCEMIC AGENTS; MILK THISTLE; PHYTOTHERAPY; PLANT EXTRACTS; PPAR GAMMA; RATS; SEEDS; SILYMARIN;

EID: 84908061964     PISSN: 16136071     EISSN: 16140575     Source Type: Journal    
DOI: 10.1900/RDS.2014.11.167     Document Type: Review

References (45)

1. Shojaii A, Dabaghian FH, Goushegir A, Fard MA. Antidiabetic plants of Iran. Acta Med Iran 2011. 49(10):637-642.
2. McCarty MF. Potential utility of natural polyphenols for reversing fat-induced insulin resistance. Med Hypotheses 2005. 64(3):628-635.
3. Wei F, Liu SK, Liu XY, Li ZJ, Li B, Zhou YL, Zhang HY, Li YW. Meta-analysis: silymarin and its combination therapy for the treatment of chronic hepatitis B. Eur J Clin Microbiol Infect Dis 2013. 32(5):657-669.
4. Biedermann D, Vavrikova E, Cvak L, Kren V. Chemistry of silybin. Nat Prod Rep 2014. 31(9):1138-1157.
5. Santos J, Mira LB, Freire AM, Azevedo M, Manso C. Placental aldose reductase inhibition by Silybin. Acta Medica Port 1984. 5(4-5):115-117.
6. Di Giulio AM, Lesma E, Germani E, Gorio A. Inhibition of high glucose-induced protein mono-ADPribosylation restores neuritogenesis and sodium-pump activity in SY5Y neuroblastoma cells. J Neurosci Res 1999. 46(5):565-571.
7. Guigas B, Naboulsi R, Villanueva GR, Taleux N, Lopez-Novoa JM, Leverve XM, El-Mir LY. The flavonoid silibinin decreases glucose-6-phosphate hydrolysis in perifused rat hepatocytes by an inhibitory effect on glucose-6-phosphatase. Cell Physiol Biochem 2007. 20(6):925-934.
8. Park. Silibinin attenuates adipogenesis in 3T3-L1 preadipocytes through a potential upregulation of the insig pathway. Int J Mol Med 2009. 23:633-637.
9. Cheng B, Gong H, Li X, Sun Y, Zhang X, Chen H, Liu X, Zheng L, Huang KL. Silibinin inhibits the toxic aggregation of human islet amyloid polypeptide. Biochem Biophys Res Commun 2012. 419(3):495-499.
10. Pferschy-Wenzig EM, Atanasov AG, Malainer C, Noha SM, Kunert O, Schuster D, Heiss EH, Oberlies NH, Wagner H, Bauer R, et al. Identification of Isosilybin A from Milk Thistle Seeds as an Agonist of Peroxisome Proliferator-Activated Receptor Gamma. J Nat Prod 2014. 77(4):842-847.
11. Detaille D, Sanchez C, Sanz N, Lopez-Novoa JM, Leverve X, El-Mir MY. Interrelation between the inhibition of glycolytic flux by silibinin and the lowering of mitochondrial ROS production in perifused rat hepatocytes. Life Sci 2008. 82(21-22):1070-1076.
12. Di Giulio AM. Alterations of protein mono-ADPribosylation and diabetic neuropathy: a novel pharmacological approach. Eur J Pharmacol 1996. 311(1):21-28.
13. Nasri H. Effect of silymarin on streptozotocinnicotinamide-induced type 2 diabetic nephropathy in rats. Iran J Kidn Dis 2013. 7(5):414-415.
14. Soto CP, Perez BL, Favari L., Reyes JL. Prevention of alloxan-induced diabetes mellitus in the rat by silymarin. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 1998. 119(2):125-129.
15. Soto C, Mena R, Luna J, Cerbon M, Larrieta E, Vital P, Uria E, Sanchez M, Recoba R, Barron H, et al. Silymarin induces recovery of pancreatic function after alloxan damage in rats. Life Sci 2004. 75(18):2167-2180.
16. Soto C, Raya L, Perez J, Gonzalez I, Perez S. Silymarin induces expression of pancreatic Nkx6.1 transcription factor and beta-cell neogenesis in a pancreatectomy model. Molecules 2014. 19(4):4654-4668.
17. Volti GL, Salomone S, Sorrenti V, Mangiameli A, Urso V, Siarkos I. Effect of silibinin on endothelial dysfunction and ADMA levels in obese diabetic mice. Cardiovasc Diabetol 2011. 10:62.
18. Zhang HT, Shi K, Baskota A, Zhou FL, Chen YX, Tian HM. Silybin reduces obliterated retinal capillaries in experimental diabetic retinopathy in rats. Eur J Pharmacol 2014. 740:233-239.
19. Soto C, Recoba R, Barrón H, Alvarez C, Favari L. Silymarin increases antioxidant enzymes in alloxan-induced diabetes in rat pancreas. Comp Biochem Physiol Part C Toxicol Pharmacol 2003. 136(3):205-212.
20. Das S, Roy P, Pal R, Auddy RG, Chakraborti AS, Mukherjee A. Engineered silybin nanoparticles educe efficient control in experimental diabetes. Plos One 2014. 9(7):e101818.
21. Haddad Y, Vallerand D, Brault A, Haddad PS. Antioxidant and hepatoprotective effects of silibinin in a rat model of nonalcoholic steatohepatitis. Evid Based Complement Alternat Med 2011. 2011:1-10.
22. Yao J, Zhi M, Gao X, Hu P, Li C, Yang X. Effect and the probable mechanisms of silibinin in regulating insulin resistance in the liver of rats with non-alcoholic fatty liver. Braz J Med Biol Res 2013. 46(3):270-277.
23. Von Shonfled, Weisbrod B, Muller MK. Silibinin, a plant extract with anti-oxidant and membrane stabilizing properties, protects exocrine pancreas form cyclosporine A toxicity. Cell Mol Life Sci 1997. 53(11-12):917-920.
24. Nomura M, Takahashi T, Nagata N, Tsutsumi K, Kobayashi S, Akiba T, Yokogawa K, Moritani S, Miyamoto K. Inhibitory mechanisms of flavonoids on insulinstimulated glucose uptake in MC3T3-G2/PA6 adipose cells. Biol Pharm Bull 2008. 31(7):1403-1409.
25. Maghrani M, Zeggwagh NA, Lemhadri A, El Amraoui M, Michel JB, Eddouks M. Study of the hypoglycaemic activity of Fraxinus excelsior and Silybum marianum in an animal model of type 1 diabetes mellitus. J Ethnopharmacol 2004. 91(2-3):309-316.
26. Bouderba S, Sanchez-Martin C, Villanueva GR, Detaille D, Koceir EA. Beneficial effects of silibinin against the progression of metabolic syndrome, increased oxidative stress, and liver steatosis in Psammomys obesus, a relevant animal model of human obesity and diabetes. J Diabetes 2014. 6(2):184-192.
27. Baluchnejadmojarad T, Roghani M, Khastehkhodaie Z. Chronic treatment of silymarin improves hyperalgesia and motor nerve conduction velocity in diabetic neuropathic rat. Phytother Res 2010. 24(8):1120-1125.
28. Velussi M, Cernigoi AM, Viezzoli L, Dapas F, Caffau C, Zilli M. Silymarin reduces hyperinsulinemia, malondialdehyde levels, and daily insulin need in cirrhotic diabetic patients. Curr Therap Res 1993. 53(5):533-545.
29. Dietzmann J, Thiel U, Ansorge S, Neumann KH, Tüger M. Thiol-inducing and immunoregulatory effects of flavonoids in peripheral blood mononuclear cells from patients with end-stage diabetic nephropathy. Free Radic Biol Med 2002. 33(10):1347-1354.
30. Fallahzadeh MK, Dormanesh B, Sagheb MM, Roozbeh J, Vessal G, Pakfetrat M, Daneshbod Y, Kamali-Sarvestani E, Lankarani KB. Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial. Am J Kidney Dis 2012. 60(6):896-903.
31. Huseini HF, Larijani B, Heshmat R, Fakhrzadeh H, Radjabipour B, Toliat T, Raza M. The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebocontrolled, clinical trial. Phytother Res 2006. 20(12):1036-1039.
32. Di Pierro F, Putignano P, Montesi L, Moscatiello S, Marchesini Reggiani G, Villanova N. Preliminary study about the possible glycemic clinical advantage in using a fixed combination of Berberis aristata and Silybum marianum standardized extracts versus only Berberis aristata in patients with type 2 diabetes. Clin Pharmacol 2013. 5:167-174.
33. Hawke RL, Schrieber SJ, Soule TA, Wen Z, Smith PC, Reddy KR, Hawed AS, Belle SH, Afdhal NH, Navarro NJ, et al. Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C. J Clin Pharmacol 2010. 50(4):434-449.
34. Gordon A, Hobbs DA, Bowden DS, Bailey MJ, Mitchell J, Francis AJ, Roberts SK. Effects of Silybum marianum on serum hepatitis C virus RNA, alanine aminotransferase levels and well-being in patients with chronic hepatitis C. J Gastroenterol Hepatol 2006. 21(1):275-280.
35. Angulo P, Jorgensen RA, Kowdley KV, Lindor KD. Silymarin in the treatment of patients with primary sclerosing cholangitis: an open-label pilot study. Dig Dis Sci 2008. 53(6):1716-1720.
36. Valentova K, Stejskal D, Bartek J, Dvorackova S, Kren V, Ulrichova J, Simanek V. Maca (Lepidium meyenii) and yacon (Smallanthus sonchifolius) in combination with silymarin as food supplements: in vivo safety assessment. Food Chem Toxicol 2008. 46(3):1006-1013.
37. Di Pierro F, Callegari A, Carotenuto D, Tapia MM. Clinical efficacy, safety and tolerability of BIO-C (micronized Silymarin) as a galactagogue. Acta Biomed 2008. 79(3):205-210.
38. Altaei T. The treatment of melasma by silymarin cream. BMC Dermatol 2012. 12(1):18.
39. Ferenci P, Beinhardt S. Silibinin: an old drug in the high tech era of liver transplantation. J Hepatol 2013. 58(3):409-411.
40. Lecomte J. Les proprietes pharmacologiques de la silybine et de la silymarine. Rev Med Liege 1975. 30:110-114.
41. Tamayo C, Diamond S. Review of clinical trials evaluating safety and efficacy of milk thistle (Silybum marianum (L.) Gaertn). Integr Cancer Ther 2007. 6(2):146-157.
42. Wu JW, Lin LC, Tsai TH. Drug-drug interactions of silymarin on the perspective of pharmacokinetics. J Ethnopharmacol 2009. 121(2):185-193.
43. Kidd PM. Bioavailability and activity of phytosome complexes from botanical polyphenols: the silymarin, curcumin, green tea, and grape seed extracts. Altern Med Rev 2009. 14(3):226-246.
44. Duan R, Sun X, Liu J, Gong T, Zhang Z. Mixed micelles loaded with silybin-polyene phosphatidylcholine complex improve drug solubility. Acta Pharmacol Sin 2010. 32(1):108-115.
45. Kim YC, Kim EJ, Lee ED, Kim JH, Jang SW, Kim YG, Kwon JW, Kim WB, Lee MG. Comparative bioavailability of silibinin in healthy male volunteers. Int J Clin Pharmacol Ther 2003. 41(12):593-596.